These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10733432)

  • 1. Endothelins are potent vasoconstrictors, and much more besides.
    Gray GA; Battistini B; Webb DJ
    Trends Pharmacol Sci; 2000 Feb; 21(2):38-40. PubMed ID: 10733432
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent developments in endothelin research.
    Bennett T; Gardiner SM
    J Hum Hypertens; 1994 Aug; 8(8):587-92. PubMed ID: 7990086
    [No Abstract]   [Full Text] [Related]  

  • 3. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
    De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
    J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin receptor antagonists: actions and rationale for their development.
    Warner TD; Battistini B; Doherty AM; Corder R
    Biochem Pharmacol; 1994 Aug; 48(4):625-35. PubMed ID: 8080434
    [No Abstract]   [Full Text] [Related]  

  • 5. The discovery of endothelins.
    Masaki T
    Cardiovasc Res; 1998 Sep; 39(3):530-3. PubMed ID: 9861293
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of the pharmacological effects of endothelin.
    Wilson C; Hargreaves RB
    Prog Med Chem; 1994; 31():371-410. PubMed ID: 8029479
    [No Abstract]   [Full Text] [Related]  

  • 7. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
    Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.
    Maguire JJ; Kuc RE; Davenport AP
    Br J Pharmacol; 2001 Nov; 134(6):1360-6. PubMed ID: 11704658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice.
    De Campo BA; Goldie RG; Jeng AY; Henry PJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():353S-356S. PubMed ID: 12193121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endothelin system in human saphenous vein graft disease.
    Davenport AP; Maguire JJ
    Curr Opin Pharmacol; 2001 Apr; 1(2):176-82. PubMed ID: 11714093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
    Yap EY; Battistini B; McKay KO
    Br J Pharmacol; 2000 Jan; 129(1):170-6. PubMed ID: 10694217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo role of endothelin-converting enzyme-1 as examined by adenovirus-mediated overexpression in rats.
    Télémaque S; Emoto N; deWit D; Yanagisawa M
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S548-50. PubMed ID: 9595539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction.
    Matsumoto T; Ozawa Y; Taguchi K; Kobayashi T; Kamata K
    Peptides; 2010 Feb; 31(2):346-53. PubMed ID: 19962413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for endothelin antagonists in diabetic renal disease?
    Jandeleit-Dahm K; Allen TJ; Youssef S; Gilbert RE; Cooper ME
    Diabetes Obes Metab; 2000 Jan; 2(1):15-24. PubMed ID: 11220349
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
    Battistini B; Verreault M; Ayach B; Blouin A; Cernacek P; Jeng AY; Wessale J; Opgenorth T; Tsang J
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S386-9. PubMed ID: 15838327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. California dreamin' 'bout endothelin: emerging new therapeutics.
    Warner TD; Elliott JD; Ohlstein EH
    Trends Pharmacol Sci; 1996 May; 17(5):177-81. PubMed ID: 8669122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endothelin and kidney disease].
    Nakayama Y; Tomita K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():655-60. PubMed ID: 15506468
    [No Abstract]   [Full Text] [Related]  

  • 18. [Involvement of endothelin in the pathogenesis of hypertension and hypertensive target-organ damage].
    Kanno K; Hirata Y
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():164-8. PubMed ID: 15171363
    [No Abstract]   [Full Text] [Related]  

  • 19. Endothelin.
    Kawanabe Y; Nauli SM
    Cell Mol Life Sci; 2011 Jan; 68(2):195-203. PubMed ID: 20848158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
    De Lombaert S; Ghai RD; Jeng AY; Trapani AJ; Webb RL
    Biochem Biophys Res Commun; 1994 Oct; 204(1):407-12. PubMed ID: 7945387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.